CENTER FOR DRUG EVALUATION AND RESEARCH APPROVAL PACKAGE FOR: APPLICATION NUMBER

21-663

Chemistry Review(s)

NDA 21-663

Menopur Injection

Ferring Pharmaceuticals Inc.

Martin Haber, Ph.D.

Division of Metabolism and Endocrine Drug Products

Consult Review For: Division of Reproductive and Urologic Drug Products



Table of Contents

Table of Contents	2
Chemistry Review Data Sheet	5
The Executive Summary	9
I. Recommendations	9
A. Recommendation and Conclusion on Approvability	9
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	9
II. Summary of Chemistry Assessments	9
A. Description of the Drug Product(s) and Drug Substance(s)	9
B. Description of How the Drug Product is Intended to be Used	. 10
C. Basis for Approvability or Not-Approval Recommendation	. 10
III. Administrative	. 10
A. Reviewer's Signature	. 10
B. Endorsement Block	. 10
C. CC Block	. 10
Chemistry Assessment	.11
I. DRUG SUBSTANCE	.11
Description & Characterization Description Description / Proof Of Structure	11
2. Manufacturer	.11
Synthesis / Method Of Manufacture a. Starting Materials - Specs & Tests b. Solvents, Reagents, etc	11
c. Flow Chart	
d. Detailed Description	11





	4. Process Controls Error! Bookmar	k not defined.
	a. Reaction Completion / Other In-Process Tests	12
	a. Preparation	12
	6. Regulatory Specifications / Analytical Methods	12
	a. Drug Substance Specifications & Tests	12
	b. Purity Profile	13
	c. Microbiology	13
	7. Container/Closure System For Drug Substance Storage	13
	8. Drug Substance Stability	13
II.	DRUG PRODUCT	14
	1. Components/Composition	14
	2. Specifications & Methods For Drug Product Ingredients	14
	a. Active Ingredient(s)	14
	b. Inactive Ingredients	14
	3. Manufacturer	14
	4. Methods Of Manufacturing And Packaging	14
	a. Production Operations	14
	b. In-Process Controls & Tests	14
	c. Reprocessing Operations	14
	5. Regulatory Specifications And Methods For Drug Product	15
	a. Sampling Procedures	15
	b. Regulatory Specifications And Methods	15
	6. Container/Closure System	15
	7. Microbiology	15
	8. Drug Product Stability	15
Ш	. INVESTIGATIONAL FORMULATIONS	15
IV.	ENVIRONMENTAL ASSESSMENT	16
v.	METHODS VALIDATION	16
VI.	LABELING	16

CDED	CHEMISTRY REVIEW #2		GIVE
17	MENT INSPECTION	ESTABLISHM	VII.
18	CIENCY LETTER	DRAFT DEFI	VIII.

Appears This Way
On Original



Chemistry Review Data Sheet

Chemistry Review Data Sheet

- 1. NDA 21-663
- 2. REVIEW #: 2
- 3. REVIEW DATE: October 22, 2004
- 4. REVIEWER: Martin Haber, Ph.D.
- 5. PREVIOUS DOCUMENTS:

Document Date
12/28/03
2/26/04
5/10/04
7/30/04
8/6/04

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed	Document Date
Amendment (response to teleconference)	8/3/04
Amendment (response to Biopharm request)	8/5/04
Amendment (response to FDA CMC IR letter)	8/10/04

7. NAME & ADDRESS OF APPLICANT:

Name: Ferring Pharmaceuticals Inc.

Address: 400 Rella Boulevard, Suite 300, Suffern, NY 10901

Representative: James Conover, Ph.D.

Telephone: 845-770-2600



Chemistry Review Data Sheet

δ.	DRUG PRODUCT NAME/CODE/TYPE:
	a) Proprietary Name: b) Non-Proprietary Name (USAN): C) Code Name/# (ONDC only): D) Chem. Type/Submission Priority (ONDC only): Chem. Type: 3 Submission Priority: S
9.	LEGAL BASIS FOR SUBMISSION: NA
10	. PHARMACOL. CATEGORY: Fertility: [
11	. DOSAGE FORM: Lyophilized powder for injection
12	. STRENGTH/POTENCY: Single dose vial 75 IU of FSH and LH
13	. ROUTE OF ADMINISTRATION: SC or IM Injection
14	. Rx/OTC DISPENSED: _X_RxOTC
15	. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM): XSPOTS product – Form Completed
	Not a SPOTS product
16	CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT: Human menopausal gonadotropins (HMG) preparation containing approximately equal amounts of follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity extracted from the urine of postmenopausal women. FSH and LH are both acidic glycoproteins, each consisting of two subunits of about 25 kDa molecular weight, including carbohydrates. The common α subunit contains 92 amino acids. The β subunits are unique to each hormone, the β subunits of FSH and LH contain 111 and 121 amino acids, respectively. Another acidic glycoprotein, human Chorionic Gonadotropin (hCG) is also present in the drug substance and it contributes to the LH activity. The β subunit of the hCG glycoprotein contains 145 amino acids. Other urinary

proteins are also present as impurities; however, this NDA preparation is about 25-fold

more purified than traditional menotropins preparations.





Chemistry Review Data Sheet

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	ТҮРЕ	HOLDER	ITEM REFERENCED	CODE	STATUS ²	DATE REVIEW COMPLETED	REVIEWER/ COMMENTS
_	III	-		3	Adequate	10/22/99	Dr. Harapanhalli, NDA 21092
	III			3	Adequate	1/4/01	Dr. Powers, ANDA 74802
-	II		HMG	3	Adequate	1994	Dr. C-H. Niu, ANDA 73598
L							

¹ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

- 2 Type 1 DMF
- 3 Reviewed previously and no revision since last review
- 4 Sufficient information in application
- 5 Authority to reference not granted
- 6 DMF not available
- 7 Other (explain under "Comments")

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
IND	53,954	Repronex (Menotropins for injection, USP)
NDA	21-047	Repronex (Menotropins for injection, USP)
NDA	21-289/484	Bravelle (Urofollitropin for injection, purified)

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)





Chemistry Review Data Sheet

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	NA		
EES	Pending		
Pharm/Tox	NA		
Biopharm	NA		
Methods Validation	Pending		
ODS/DMETS	Tradename Acceptable	2/10/04	L. Wisniewski
EA	Categorical exclusion granted	10/22/04	M. Haber
Microbiology	Approval	10/5/04	J. McVey

Appears This Way On Original



3

ı

1

Executive Summary Section

The Chemistry Review for NDA 21-663

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Recommend Approval pending an acceptable cGMP inspection status.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

NA

L

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The Menopur drug product contains 75 IU of FSH activity and 75 IU of LH activity in a sterile, lyophilized preparation in a glass vial with a rubber stopper and metal overseal. The excipients are — mg of lactose, 5 mcg of polysorbate 20 and small traces of sodium phosphate for pH adjustment. The drug product is manufactured by Cardinal Health, Albuquerque, NM. The bulk solution is C

The drug substance is a C J purified extract from the urine of

postmenopausal and menopausal women that contains the gonadotropin hormones, FSH, LH and hCG. Hormone activity for FSH and LH is measured in International Units using rat bioassays relative to an international reference standard. The drug substance is manufactured by the formula of the drug substance is more purified than the currently marketed menotropins product, therefore the amount of contaminating urinary

Both FSH and LH are purified through C

proteins is much reduced (about 25-fold).

7 The FSH and LH activity ratio is adjusted to about 1:1 by

The drug substance quality is mainly controlled by bioassay testing for FSH and LH activity and measurement of the protein content. The percent aggregation is





Executive Summary Section

limited to NMT — Specifications also include microbial bioburden and viral safety testing. The drug substance has been shown to be stable for 48 months at 2-8°C, the recommended storage temperature.

B. Description of How the Drug Product is Intended to be Used

Menopur is indicated fo — 1 The dose used must be individualized for each patient by a physician experienced in providing fertility treatments. The drug product is a sterile, lyophilized, single-dose preparation in a glass vial containing 75 IU of FSH and 75 IU of LH bioactivity. Only one strength is proposed. The package also contains a 2 mL vial of 0.9% Sodium Chloride Injection, USP, diluent for use in reconstituting the solution for SC or IM injection. The expiration period is 24 months stored at refrigerated or room temperature.

C. Basis for Approvability or Not-Approval Recommendation

The firm has provided adequate chemistry manufacturing and controls information. The manufacturing processes for both drug substance and product are adequately described. The specifications for both drug substance and product are adequate. The drug product stability is adequate to support an expiry date of 24 months at either refrigerated or room temperature. A product quality microbiology review dated 10/5/04 found the application acceptable. The application is acceptable from a chemistry viewpoint, pending an acceptable and the status of cGMP inspections.

III. Administrative

A. Reviewer's Signature

See DFS

B. Endorsement Block

See DFS

C. CC Block

See DFS

8 Page(s) Withheld

- § 552(b)(4) Trade Secret / Confidential
- _____ § 552(b)(5) Deliberative Process
- _____ § 552(b)(5) Draft Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Martin Haber 10/22/04 04:06:33 PM CHEMIST

approval pending acceptable EER

Moo-Jhong Rhee 10/26/04 02:29:01 PM CHEMIST I concur





NDA 21-663

Menopur Injection

Ferring Pharmaceuticals Inc.

Martin Haber, Ph.D.

Division of Metabolism and Endocrine Drug Products

Consult Review For:
Division of Reproductive and Urologic Drug Products

Table of Contents

Tabl	le of Contents	2
Chei	mistry Review Data Sheet	5
The	Executive Summary	9
I.	Recommendations	9
	A. Recommendation and Conclusion on Approvability	9
	B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable	9
II	. Summary of Chemistry Assessments	9
	A. Description of the Drug Product(s) and Drug Substance(s)	9
	B. Description of How the Drug Product is Intended to be Used	10
	C. Basis for Approvability or Not-Approval Recommendation	10
11	I. Administrative	10
	A. Reviewer's Signature	10
	B. Endorsement Block	10
	C. CC Block	10
Cher	mistry Assessment	11
I.	DRUG SUBSTANCE	11
	1. Description & Characterization	11
	a. Description	11
	b. Characterization / Proof Of Structure	12
	2. Manufacturer	18
	3. Synthesis / Method Of Manufacture	18
	a. Starting Materials - Specs & Tests	18
	b. Solvents, Reagents, etc.	20





c. Flow Chart	
d. Detailed Description	24
4. Process ControlsError! Bookm	ark not defined
a. Reaction Completion / Other In-Process Tests	
a. Preparation	33
6. Regulatory Specifications / Analytical Methods	35
a. Drug Substance Specifications & Tests	35
b. Purity Profile	39
c. Microbiology	41
7. Container/Closure System For Drug Substance Storage	41
8. Drug Substance Stability	42
II. DRUG PRODUCT	43
1. Components/Composition	43
2. Specifications & Methods For Drug Product Ingredients	.4 4
a. Active Ingredient(s)	4 4
b. Inactive Ingredients	44
3. Manufacturer	45
4. Methods Of Manufacturing And Packaging	46
a. Production Operations	46
b. In-Process Controls & Tests	49
c. Reprocessing Operations	50
5. Regulatory Specifications And Methods For Drug Product	50
a. Sampling Procedures	50
b. Regulatory Specifications And Methods	50
6. Container/Closure System	52
7. Microbiology	52
8. Drug Product Stability	53
III.INVESTIGATIONAL FORMULATIONS	54
IV. ENVIRONMENTAL ASSESSMENT	55
V. METHODS VALIDATION	55

	CHEMISTRY REVIEW	Garden Statement and Branch
VI. LABELING		55
VII. ESTABLISH	MENT INSPECTION	57
VIII. DRAFT DEFI	CIENCY LETTER	58

Appears This Way On Original



Chemistry Review Data Sheet

Chemistry Review Data Sheet

- 1. NDA 21-663
- 2. REVIEW #: 1
- 3. REVIEW DATE: August 5, 2004
- 4. REVIEWER: Martin Haber, Ph.D.
- 5. PREVIOUS DOCUMENTS:

Previous Documents

Document Date

Initial CMC Filing Memorandum

2/26/04

6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed

Document Date

Original NDA (10 Volumes)

12/28/03

Amendment (response to Filing comments)

5/10/04

7. NAME & ADDRESS OF APPLICANT:

Name:

Ferring Pharmaceuticals Inc.

Address:

400 Rella Boulevard, Suite 300, Suffern, NY

10901

Representative:

James Conover, Ph.D.

Telephone:

845-770-2600





Chemistry Review Data Sheet

8.	DRUG PRODUCT NAME/CODE/TYPE:					
	a) Proprietary Name: Menopur b) Non-Proprietary Name (USAN): Menotropins for Injection, USP c) Code Name/# (ONDC only): Purified Repronex d) Chem. Type/Submission Priority (ONDC only): • Chem. Type: 3 • Submission Priority: S					
9.	LEGAL BASIS FOR SUBMISSION: NA					
10	. PHARMACOL. CATEGORY: Fertility —					
11	. DOSAGE FORM: Lyophilized powder for injection					
12	. STRENGTH/POTENCY: Single dose vial 75 IU of FSH and LH					
13	. ROUTE OF ADMINISTRATION: SC or IM Injection					
14	. Rx/OTC DISPENSED: _X_RxOTC					
15	. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM): XSPOTS product – Form Completed					
	Not a SPOTS product					
16	CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT: Human menopausal gonadotropins (HMG) preparation containing approximately equal amounts of follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity extracted from the urine of postmenopausal women. FSH and LH are both acidic glycoproteins, each consisting of two subunits of about 25 kDa molecular weight, including carbohydrates. The common α subunit contains 92 amino acids. The β subunits are unique to each hormone, the β subunits of FSH and LH contain 111 and 121 amino acids, respectively. Another acidic glycoprotein, human Chorionic					

menotropins preparations.

Gonadotropin (hCG) is also present and contributes to the LH activity. The β subunit of the hCG glycoprotein contains 145 amino acids. Other urinary proteins are also present as impurities; however, this NDA preparation is about 25-fold more purified than traditional





Chemistry Review Data Sheet

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

DMF #	ТҮРЕ	HOLDER	ITEM REFERENCED	CODE	STATUS ²	DATE REVIEW COMPLETED	REVIEWER/ COMMENTS
	III			3	Adequate	10/22/99	Dr. Harapanhalli, NDA 21092
_	III			3	Adequate	1/4/01	Dr. Powers, ANDA 74802
_			HMG	3	Adequate	1994	Dr. C-H. Niu, ANDA 73598

¹ Action codes for DMF Table:

1 – DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

- 2-Type 1 DMF
- 3 Reviewed previously and no revision since last review
- 4 Sufficient information in application
- 5 Authority to reference not granted
- 6 DMF not available
- 7 Other (explain under "Comments")

B. Other Documents:

APPLICATION NUMBER	DESCRIPTION
53,954	Repronex (Menotropins for injection, USP)
21-047	Repronex (Menotropins for injection, USP)
21-289	Bravelle (Urofollitropin for injection, purified)
	53,954 21-047

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)





Chemistry Review Data Sheet

18. STATUS:

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Biometrics	NA		
EES	Pending		
Pharm/Tox	NA		
Biopharm	NA		
Methods Validation	Pending		
ODS/DMETS	Tradename Acceptable	2/10/04	L. Wisniewski
EA	Categorical exclusion granted		
Microbiology	Pending		J. McVey

Appears This Way On Original



Executive Summary Section

The Chemistry Review for NDA 21-663

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Recommend Approval pending a satisfactory response to requests for additional chemistry information, and acceptable microbiology review and cGMP inspection status.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

NA

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

The Menopur drug product contains 75 IU of FSH activity and 75 IU of LH activity in a sterile, lyophilized preparation in a glass vial with a rubber stopper and metal overseal. The excipients are — mg of lactose, 5 mcg of polysorbate 20 and small traces of sodium phosphate for pH adjustment. The drug product is manufactured by Cardinal Health, Albuquerque, NM. The bulk solution is

The drug substance is a — purified extract from the urine of postmenopausal and menopausal women that contains the gonadotropin hormones, FSH, LH and hCG. Hormone activity for FSH and LH is measured in International Units using rat bioassays relative to an international reference standard. The drug substance is manufactured by C

J from urine collected from about — women donors living around — The drug substance is more purified than the currently marketed menotropins product, therefore the amount of contaminating urinary proteins is much reduced (about 25-fold).

Both FSH and LH are purified through $\, \subset \,$

I

[





Executive Summary Section

The drug substance quality is mainly controlled by bioassay testing for FSH and LH activity and measurement of the protein content. The percent aggregation is limited to NMT —— Specifications also include microbial bioburden and viral safety testing. The drug substance has been shown to be stable for 48 months at 2-8°C, the recommended storage temperature.

B. Description of How the Drug Product is Intended to be Used

Menopur is indicated for L 1 The dose used must be individualized for each patient by a physician experienced in providing fertility treatments. The drug product is a sterile, lyophilized, single-dose preparation in a glass vial containing 75 IU of FSH and 75 IU of LH bioactivity. Only one strength is proposed. The package also contains a 2 mL vial of 0.9% Sodium Chloride Injection, USP, diluent for use in reconstituting the solution for SC injection. The proposed expiration period is 24 months stored at refrigerated or room temperature.

C. Basis for Approvability or Not-Approval Recommendation

The firm has provided adequate chemistry manufacturing and controls information. The manufacturing processes for both drug substance and product are adequately described. The specifications for both drug substance and product are adequate. The drug product stability is adequate to support an expiry date of 24 months at either refrigerated or room temperature. The application is acceptable from a chemistry viewpoint, pending an adequate response to the comments delineated in Section VIII of the Chemistry Assessment. In addition, microbiology review and the status of cGMP inspections are pending.

III. Administrative

A. Reviewer's Signature

See DFS

B. Endorsement Block

See DFS

C. CC Block

See DFS

48 Page(s) Withheld

- § 552(b)(4) Trade Secret / Confidential
 - ___ § 552(b)(5) Deliberative Process
- _____ § 552(b)(5) Draft Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Martin Haber 8/6/04 11:38:53 AM CHEMIST

Moo-Jhong Rhee 8/6/04 02:50:01 PM CHEMIST I concur

NDA 21-663

Menopur® (menotropins for injection USP)

Ferring Pharmaceuticals

Project Manager Martin Kaufman HFD-580 301-827-4234

Environmental Assessment

Please refer to page 55 of the August 5, 2004 Chemistry Review



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration

Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drug Products

Memorandum

Date:

October 27, 2004

From:

Martin Haber, Ph.D., Review Chemist, HFD-510

Subject:

Establishment Evaluation

To:

NDA 21-663 Menopur

Chemistry Review #2, dated 10/22/04, recommended approval for NDA 21-663 from a chemistry viewpoint, pending a recommendation regarding the cGMP inspection status of the manufacturing facilities by the Office of Compliance (OC). An establishment evaluation from the OC for the NDA has now been received, see attachment. The cGMP status of all facilities is acceptable. Therefore, the overall recommendation from chemistry for the NDA is approval.

R/D Init by: Dr. M-J. Rhee, Chemistry Team Leader

Orig. NDA 21-663

cc: HFD-580/Division file/M.Haber/

1 of 3

ESTABLISHMENT EVALUATION REQUEST

SUMMARY REPORT

Application : NDA 21663/000

Sponsor: FERRING

Org Code

: 580

400 RELLA BLVD STE 300

Priority : 3S

SUFFERN, NY 10901

Stamp Date : 29-DEC-2003

Brand Name :

MENOPUR (MENOTROPINS)

PDUFA Date : 29-OCT-2004

INJECTION 75IU

Action Goal :

District Goal: 30-AUG-2004

Estab. Name:

Generic Name: MENOTROPINS

Dosage Form:

(FOR INJECTION)

Strength : 75 IU FSH/ 75 IU LH

FDA Contacts: M. KAUFMAN

Project Manager (HFD-580) 301-827-4260

M. HABER

Review Chemist (HFD-510)

301-827-6420

M. RHEE

Team Leader

(HFD-580)

301-827-4237

Overall Recommendation:

ACCEPTABLE on 27-OCT-2004by S. ADAMS (HFD-322) 301-827-9051

Establishment : CFN :

FEI :

DMF No:

AADA:

Responsibilities:

Profile

OAI Statue: NONE

Last Milestone:

OC RECOMMENDATION

Milestone Date:

24-FEB-04

Decision

ACCEPTABLE

DISTRICT RECOMMENDATION

Establishment : CFN :

FEI

DMF No:

AADA:

Profile : OAI Status: NONE

Last Milestone: OC RECOMMENDATION

Milestone Date: 27-FEB-04

Decision : ACCEPTABLE

Reason : DISTRICT RECOMMENDATION

Establishment: CFN: FEI:

Responsibilities:

27-OCT-2004

ESTABLISHMENT EVALUATION REQUEST

SUMMARY REPORT

Profile :

CTL

OAI Status: NONE

Last Milestone:

OC RECOMMENDATION

Milestone Date:

09-FEB-04

Decision

ACCEPTABLE

BASED ON PROFILE

Establishment : CFN : 1643045

FEI : 1643045

CARDINAL HEALTH MANUFACTURING SERVICES B V

4200 4272 BALLOON PARK ROAD NE

ALBUQUERQUE, NM 87109

DMF No:

AADA:

Responsibilities:

DRUG SUBSTANCE RELEASE TESTER

FINISHED DOSAGE MANUFACTURER

Profile :

SVL

OAI Status: NONE

Last Milestone:

OC RECOMMENDATION

Milestone Date:

13-FEB-04

Decision : ACCEPTABLE

į

Reason

DISTRICT RECOMMENDATION

Establishment : CFN :

:

FEI :

DMF No:

AADA:

Responsibilities:

Profile

CTL

OAI Status: NONE

Last Milestone:

:

:

OC RECOMMENDATION

Milestone Date:

09-FEB-04

Decision

ACCEPTABLE

BASED ON PROFILE

Establishment : CFN :

FEI :

DMF No:

Responsibilities:

Profile : OAI Status: NONE

OC RECOMMENDATION Last Milestone:

Milestone Date: 27-OCT-04 Decision : ACCEPTABLE

DISTRICT RECOMMENDATION Reason

Establishment : CFN : FEI:

FDA CDER EES

Page 3 of 3

AADA:

ESTABLISHMENT EVALUATION REQUEST

SUMMARY REPORT

DMF No: AADA:

Responsibilities:

Profile : CTL OAI Status:

NONE Last Milestone:

OC RECOMMENDATION Milestone Date: 09-FEB-04

ACCEPTABLE Reason BASED ON PROFILE

Decision

27-OCT-2004

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Martin Haber 10/27/04 03:01:59 PM CHEMIST

Moo-Jhong Rhee 10/27/04 04:24:39 PM CHEMIST I concur

NDA 21-663

Menopur (menotropins for injection, USP)

Ferring Pharmaceuticals

Methods Validation

Milaby

Not yet requested.